<DOC>
	<DOCNO>NCT00564928</DOCNO>
	<brief_summary>To determine : - Anti-tumor activity IPI-504 2 group subject hormone resistant prostate cancer . - Group A - subject previously receive chemotherapy - Group B - sujects receive prior chemotherapy could tolerate chemotherapy . - Clinical response determine PSA radiological response</brief_summary>
	<brief_title>A Phase 2 Study Investigate Clinical Activity IPI-504 Patients With Hormone-resistant Prostate Cancer</brief_title>
	<detailed_description>IPI-504 novel , water-soluble analog 17-AAG potent inhibitor Hsp90 . Hsp90 's role cell control proper folding , function , viability various `` client '' protein . Many client protein ( AKT , Her-2 , Bcr-Abl , PDGFR-Î± , c-Kit ) oncoproteins important cell signal protein . Inhibition HSP-90 lead proteasomal degradation protein . In patient HRPC , several protein important progression HRPC , include AR , AKT Her-2 . All client proteins Hsp90 response Hsp90 inhibition degrade proteasome . Preclinical study show Hsp90 inhibition cause dose dependent degradation client proteins growth inhibition prostate cancer xenograft tumor .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Adenocarcinoma prostate Resolution acute toxic side effect prior chemotherapy Castration resistant disease despite ongoing chemical surgical castration ECOG 01 PSA great equal 2 Group A No Prior treatment prostate cancer cytotoxic chemotherapy ( neoadjuvant , adjuvant treatment permit 2 year ) Group B Radiographic evidence metastatic disease Prior tx docetaxelminimum 2 cycle progression RECIST PSA intolerant tx Maximum 3 prior chemotherapy Small cell carcinoma prostate Treatment within 2 week approve , investigational , small molecule Treatment within 4 week biologic external beam radiation ANC &lt; 1,500 cell m3 ; Platelets &lt; 100,000 mm3 ; Hemoglobin &lt; 9.0g/dL AST/ALT &gt; 2.5 ULN Serum creatinine &gt; 3.0mg/dL Active keratitis keratoconjunctivitis Previous treatment 17AAG , DMAG ; HSP90 inhibitor Baseline Qtc &gt; 450 ms</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hormone resistant prostate cancer</keyword>
	<keyword>castrate resistant prostate cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>CRPC</keyword>
</DOC>